$ 69.15
Key Takeaways
Risk factor
High price volatility
Profitability factor
Very low or no dividends
About
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Target Price
The average target price of CRSP is 83 and suggests 20% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
